International Conference on Innovations for the Elimination and Control of Visceral Leishmaniasis (IEC-VL)

28-30 November 2018 
New Delhi, India

The major objective of the International Conference on Innovations for the Elimination and Control of Visceral Leishmaniasis (IEC-VL) is to bring together leading scientists from academia and industry around the world to deliberate upon new tools, new approaches, and routes to implementation.

 

Session

VL & PKDL– Current status from control to elimination

Date: Wednesday, 28 November 2018
Time: 11:00-12:20

Chair: Simon Croft, Professor of Parasitology, London School of Hygiene and Tropical Medicine, UK
Co-chair: Angamuthu Selvapandiyan, Team Lead Scientist, Jamia Hamdard, India

Kala-azar elimination in South Asia: Impact of the efforts so far in Nepal
Suman Rijal, Head of Regional Office, DNDi India

A path achieved towards kala-azar near-elimination in Bangladesh
Rajib Chowdhury, National Institute of Preventive and Social Medicine, Bangladesh

Overview of VL in India, past and present
Pradeep Das, Director, The Rajendra Memorial Research Institute of Medical Sciences, India

PKDL a threat in kala-azar elimination strategy in Indian Subcontinent
Ed Zijlstra, Senior Consultant, DNDi 

 

 

The tools for control: drugs/diagnostics/vaccines/transmission/surveillance

Date: Thursday, 29 November 2018
Time: 10:10-11:10

Chair: Mary Cameron, Professor, London School of Hygiene and Tropical Medicine, UK
Co-chair: Pradeep Das, Director, The Rajendra Memorial Research Institute of Medical Sciences, India

Sandfly: New vector control measures
Alon Warburg, Professor, Hebrew University of Jerusalem, Israel

Significance of vector challenge in relation to visceral leishmaniasis control: deciphering sand fly-transmitted infections
Shaden Kamhawi, The National Institute of Allergy and Infectious Diseases, NIH, USA

The role of PKDL patients in the VL transmission in Bangladesh
Jorge Alvar, Senior Leishmaniasis Advisor, DNDi, Switzerland

 

Diagnostics

Date: Thursday, 29 November 2018
Time: 9:10-10:10

Chair: Suman Rijal, Head of Regional Office, DNDi India
Co-chair: Greg Matlashewski, McGill Univ, Canada

Post kala-azar dermal leishmaniasis (PKDL): a roadblock in elimination of kala-azar
Poonam Salotra, Deputy Director, National Institute of Pathology, India

Emily Adams, Senior Lecturer in Diagnostics for Infectious Disease, Liverpool School of Tropical Medicine, UK

Diagnosis and management of VL-HIV coinfection within the elimination framework
Sakib Burza, Medical Advisor, Médecins Sans Frontières, India

Unmet diagnostic needs in leishmaniasis
Isra Cruz, Senior Scientific Officer, FIND, Switzerland

 

Drugs

Date: Thursday, 29 November 2018
Time: 11:50-13:30

Chair: Anuradha Dube, Chief Scientist, CDRi, India
Co-chair: Syamal Roy, Indian Institute of Chemical Biology, India

Current and future perspectives for the development of innovative treatments for leishmaniasis
Fabiana Alves, Head of Visceral Leishmaniasis Clinical Program, DNDi, Switzerland

Drug efficacy against PKDL
Poonam Salotra, Deputy Director, National Institute of Pathology, India

Drug discovery to combat VL in India
Neena Goel, Central Drug Research Institute, India

Therapeutic role of cholesterol in experimental visceral leishmaniasis
Syamal Roy, Indian Institute of Chemical Biology, India
The role of Thermo-therapy in the treatment of CL
Najibulla Safi, National Malaria and Leishmaniasis Control Program Manager, Ministry of Public Health, Afghanistan

 

 

More information: